96 related articles for article (PubMed ID: 3842289)
21. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.
Brown JP; Chines AA; Myers WR; Eusebio RA; Ritter-Hrncirik C; Hayes CW
Bone; 2000 Mar; 26(3):263-7. PubMed ID: 10709999
[TBL] [Abstract][Full Text] [Related]
22. Paget's disease. Radiological changes occurring in untreated patients and those on therapy with salmon calcitonin during two years' observation.
Woodhouse NJ; Chalmers AH; Wells IP; Dewbury KC; Mohamedally SM
Br J Radiol; 1977 Oct; 50(598):699-705. PubMed ID: 562693
[TBL] [Abstract][Full Text] [Related]
23. Stress fractures healing with bisphosphonates in Paget's disease.
Kumar R; Selviambigapathy JK; Kamalanathan S; Sahoo JP
Joint Bone Spine; 2017 Jan; 84(1):91. PubMed ID: 27118017
[No Abstract] [Full Text] [Related]
24. Extensive personal experience: Paget's disease of bone.
Siris ES
J Clin Endocrinol Metab; 1995 Feb; 80(2):335-8. PubMed ID: 7852484
[No Abstract] [Full Text] [Related]
25. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
26. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
27. [Amino-hydroxy-propane diphosphonate (APD): satisfactory therapeutic response in a patient with Paget's disease of bone].
García-Vadillo JA; Díaz-González F; García de Vicuña R; Gómez-Pan A
Rev Clin Esp; 1991 Apr; 188(7):379-80. PubMed ID: 1784768
[No Abstract] [Full Text] [Related]
28. Bisphosphonates in Paget's disease.
Reid IR; Hosking DJ
Bone; 2011 Jul; 49(1):89-94. PubMed ID: 20832512
[TBL] [Abstract][Full Text] [Related]
29. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
[TBL] [Abstract][Full Text] [Related]
30. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Oostendorp-van de Ruit M; Van der Pluijm G; Löwik CW; Papapoulos SE
J Bone Miner Res; 1995 Jun; 10(6):956-62. PubMed ID: 7572320
[TBL] [Abstract][Full Text] [Related]
32. Scintigraphic aspects of the recurrence of treated Paget's disease of bone.
Vellenga CJ; Pauwels EK; Bijvoet OL; Frijlink WB
J Nucl Med; 1981 Jun; 22(6):510-7. PubMed ID: 7229723
[TBL] [Abstract][Full Text] [Related]
33. [Radiologic improvement of Paget's disease of bone by porcine calcitonin therapy: a case report].
Sakino I; Onizuka H; Matsuura K; Eguchi M; Onizuka S
Rinsho Hoshasen; 1984 Mar; 29(3):431-4. PubMed ID: 6748284
[No Abstract] [Full Text] [Related]
34. Bone scintigraphy and radiology in Paget's disease of bone: a review.
Vellenga CJ; Bijvoet OL; Pauwels EK
Am J Physiol Imaging; 1988; 3(3):154-68. PubMed ID: 3056466
[TBL] [Abstract][Full Text] [Related]
35. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
[TBL] [Abstract][Full Text] [Related]
36. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
37. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
38. Paget's disease of bone: presentation, extent and response to bisphosphonates.
Wang LM; Au-Yeong ML; McKenna MJ
Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
[TBL] [Abstract][Full Text] [Related]
39. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
Papapoulos SE; Hoekman K; Löwik CW; Vermeij P; Bijvoet OL
J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
[TBL] [Abstract][Full Text] [Related]
40. Paget's disease of bone: A clinical update.
Cook SJ; Wall C
Aust J Gen Pract; 2021; 50(1-2):23-29. PubMed ID: 33543158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
